Compare FBIN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBIN | GKOS |
|---|---|---|
| Founded | 1988 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building Products | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.9B |
| IPO Year | 2011 | 2015 |
| Metric | FBIN | GKOS |
|---|---|---|
| Price | $45.25 | $103.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 14 |
| Target Price | $61.40 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 3.4M | 662.2K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.30% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.47 | N/A |
| Revenue | ★ $4,463,200,000.00 | $507,442,000.00 |
| Revenue This Year | $2.75 | $23.39 |
| Revenue Next Year | $3.64 | $27.46 |
| P/E Ratio | $18.34 | ★ N/A |
| Revenue Growth | N/A | ★ 32.33 |
| 52 Week Low | $44.04 | $73.16 |
| 52 Week High | $64.84 | $130.23 |
| Indicator | FBIN | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 28.50 | 35.28 |
| Support Level | $44.04 | $81.54 |
| Resistance Level | $53.81 | $106.52 |
| Average True Range (ATR) | 2.11 | 3.58 |
| MACD | -1.04 | -1.81 |
| Stochastic Oscillator | 7.67 | 14.28 |
Fortune Brands Innovations is a leading home and security products company that has three reportable segments. The company's $2.6 billion water segment, led by the Moen brand, sells faucets, showers, and other plumbing fixtures; the $1.4 billion outdoors segment primarily sells entry doors under the Therma-Tru brand name and Fiberon-branded patio decking; and the $700 million security segment sells locks and other security devices under the Master Lock, SentrySafe, Yale, and August brand names.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.